Recombinase Platform

About Provirex

Provirex is a private, preclinical-stage biotech developing a novel gene therapy platform for HIV cure. Its technology is based on engineered recombinases, which offer nucleotide-precision excision of viral DNA without relying on error-prone cellular repair mechanisms, potentially offering a safer alternative to CRISPR-based approaches. The company is a spin-off from the Leibniz Institute of Virology (LIV) and has secured non-dilutive funding for platform expansion. Its near-term focus is advancing its lead HIV program while exploring applications in other viral diseases like HTLV-1.

Therapeutic Areas